Zaheer Ul-Haq

Prof. Dr. Zaheer Ul-Haq

Dr. Panjwani Center for Molecular Medicine and Drug Research
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IKImtiaz Khan
Imtiaz Khan
SASajid Ali
Sajid Ali
SHShahid Hameed
Shahid Hameed
NRNasim Hasan Rama
Nasim Hasan Rama
MHMuhammad Tahir Hussain
Muhammad Tahir Hussain
MCMuhammad Iqbal Choudhary
Muhammad Iqbal Choudhary

13 April 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
SKSalman Ali Khan
Salman Ali Khan
KZKomal Zia
Komal Zia
SASajda Ashraf
Sajda Ashraf
RUReaz Uddin
Reaz Uddin
Zaheer Ul-HaqZaheer Ul-Haq
Zaheer Ul-Haq
Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CLpro) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs ( Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CLpro) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.

27 November 2023 in Current Research in Structural Biology
Verified
Journal Article
Open access
SASajda Ashraf
Sajda Ashraf
HQHina Qaiser
Hina Qaiser
STSumayya Tariq
Sumayya Tariq
Asaad KhalidAsaad Khalid
Asaad Khalid
HMHafiz A. Makeen
Hafiz A. Makeen
Zaheer Ul-HaqZaheer Ul-Haq
Zaheer Ul-Haq
Human serum albumin (HSA) is a multi-domain macromolecule with diverse ligand binding capability because of its ability to allow allosteric modulation despite being a monomeric protein. Physiologically, HSA act as the primary carrier for various exogenous and endogenous compounds and fatty acids, and alter the pharmacokinetic properties of several drugs. It has antioxidant properties and is utilized therapeutically to improve the drug delivery of pharmacological agents for the treatment of several disorders. The flexibility of albumin in holding various types of drugs coupled with a variety of modifications makes this protein a versatile drug carrier with incalculable potential in therapeutics. This review provides a brief outline of the different structural properties of HSA, and its various binding sites, moreover, an overview of the genetic, biomedical, and allosteric modulation of drugs and drug delivery aspects of HSA is also included, which may be helpful in guiding advanced clinical applications and further research on the therapeutic potential of this extraordinary protein.

1 July 2011 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
WVWolfgang Voelter
Wolfgang Voelter
FRFazal Rahim
Fazal Rahim
Sobia Ahsan HalimSobia Ahsan Halim
Sobia Ahsan Halim
MTMuhammad Taha
Muhammad Taha
MKMomin Khan
Momin Khan
MCMuhammad Iqbal Choudhary
Muhammad Iqbal Choudhary

1 July 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MCMuhammad Iqbal Choudhary
Muhammad Iqbal Choudhary
SNSarfraz Ahmad Nawaz
Sarfraz Ahmad Nawaz
Zaheer Ul-HaqZaheer Ul-Haq
Zaheer Ul-Haq
MAM. Kamran Azim
M. Kamran Azim
MGM. Nabeel Ghayur
M. Nabeel Ghayur
VAViqar Uddin Ahmad
Viqar Uddin Ahmad

1 December 2016 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
Zaheer Ul-HaqZaheer Ul-Haq
Zaheer Ul-Haq
SNSehrish Naz
Sehrish Naz
MMM. Ahmad Mesaik
M. Ahmad Mesaik